Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Momenta Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (2494)	9/14/2010 8:09:17 AM
From: idos	Respond to of 3027

Tuck, cytokine profiing or cytokine-secretion profies are in vitro assays used in studies as one parameter of a possible aspect of how Copaxone modifies immune functions. There are several studies that have used similar methods (including the one regarding Copaxone combo with albutero, posted recently on ihub, where they tested peripheral blood mononuclear cells from patients for measurements of cytokines). No doubt MNTA will use this along with many more methods but I think it will take more than that. The two bright points are - I don't see anyone but MNTA do it and the FDA is willing to consider new assays/methods.